Bouzas, CristinaPastor, RosarioGarcia, SilviaMonserrat-Mesquida, MargalidaMartínez-González, Miguel ÁngelSalas-Salvado, JordiCorella, DoloresGoday, AlbertMartínez, J AlfredoAlonso-Gómez, Ángel MFernández-Barceló, OlgaVioque, JesusRomaguera, DoraLopez-Miranda, JoséEstruch, RamonTinahones, Francisco JLapetra, JoséSerra-Majem, LluisRiquelme-Gallego, BlancaMartín-Sánchez, VicentePintó, XavierDelgado-Rodriguez, MiguelMatía, PilarVidal, JosepCardenas-Salas, Jersy-JairDaimiel, LidiaRos, EmilioToledo, EstefaníaManzanares, Josep MGonzalez-Monge, InmaculadaMuñoz, Miguel-ÁngelMartinez-Urbistondo, DiegoTojal-Sierra, LucasMuñoz-Bravo, CarlosMiralles-Gisbert, SalvadorMartin, MarianGarcía-Ríos, AntonioCastro-Barquero, SaraFernández-García, José CarlosSantos-Lozano, José ManuelBasterra-Gortari, F JavierGutiérrez-Carrasquilla, LilianaGuillem-Saiz, PatriciaSatorres, AlbaAbete, ItziarSorto-Sanchez, CarolinaDíez-Espino, JavierBabio, NancyFito, MontserratTur, Josep A2024-10-092024-10-092023-05Bouzas C, Pastor R, Garcia S, Monserrat-Mesquida M, Martínez-González MÁ, Salas-Salvadó J, et al. Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome. Biomed Pharmacother. 2023 May;161:114561.https://hdl.handle.net/20.500.13003/18899https://hdl.handle.net/20.500.12105/23621Aims: To assess the comparative effects of glucagon-like peptide-1 receptor agonists (GLP-1RA), 4-dipeptidyl peptidase inhibitors (DPP-4I), and metformin treatment during one year on metabolic syndrome (MetS) components and severity in MetS patients. Methods: Prospective study (n = 6165 adults) within the frame of PREDIMED-Plus trial. The major end-point was changes on MetS components and severity after one- year treatment of GLP-1RA, DPP-4I, and metformin. Anthropometric measurements (weight, height and waist circumference), body mass index (BM), and blood pressure were registered. Blood samples were collected after overnight fasting. Plasma glucose, glycosylated hemoglobin (HbA1c), plasma triglycerides and cholesterol were measured. Dietary intakes as well as physical activity were assessed through validated questionnaires. Results: MetS parameters improved through time. The treated groups improved glycaemia compared with untreated (glycaemia ∆ untreated: -1.7 mg/dL(± 13.5); ∆ metformin: - 2.5(± 23.9) mg/dL; ∆ DPP-4I: - 4.5(± 42.6); mg/dL ∆ GLP-1RA: - 4.3(± 50.9) mg/dL; and HbA1c: ∆ untreated: 0.0(± 0.3) %; ∆ metformin: - 0.1(± 0.7) %; ∆ DPP-4I: - 0.1(± 1.0) %; ∆ GLP-1RA: - 0.2(± 1.2) %. Participants decreased BMI and waist circumference. GLP-1RA and DPP-4I participants registered the lowest decrease in BMI (∆ untreated: -0.8(± 1.6) kg/m2; ∆ metformin: - 0.8(± 1.5) kg/m2; ∆ DPP-4I: - 0.6(± 1.3) kg/m2; ∆ GLP-1RA: - 0.5(± 1.2) kg/m2. and their waist circumference (∆ untreated: -2.8(± 5.2) cm; ∆ metformin: - 2.6(± 15.2) cm; ∆ DPP-4I: - 2.1(± 4.8) cm; ∆ GLP-1RA: - 2.4(± 4.1) cm. Conclusion: In patients with MetS and healthy lifestyle intervention, those treated with GLP-1RA and DPP-4I obtained better glycemic profile. Anthropometric improvements were modest.enghttp://creativecommons.org/licenses/by-nc-nd/4.0/Diabetes Mellitus, Type 2Metabolic SyndromeProspective StudiesDipeptidyl-Peptidases and Tripeptidyl-PeptidasesAdultHumansDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide 1MetforminHypoglycemic Agentsresearch articleAttribution-NonCommercial-NoDerivatives 4.0 Internacional3693455616111456110.1016/j.biopha.2023.1145611950-6007Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapieopen accessInhibidores de la Dipeptidil-Peptidasa IVMetforminaHipoglucemiantesHumanosPéptido 1 Similar al GlucagónEstudios ProspectivosSíndrome MetabólicoDiabetes Mellitus Tipo 2AdultoDipeptidil-Peptidasas y Tripeptidil-Peptidasas2-s2.0-85150299997L2023388104